Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for CRB-701, a next-gen antibody drug conjugate targeting Nectin-4, showing promising activity in second-line oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. The confirmed objective response rates were 42.9% for OPSCC and 34.4% for cervical cancer at the 3.6 mg/kg dose, with manageable safety profiles and low discontinuation rates. These results support Corbus' strategy to target tumors with high Nectin-4 expression and unmet medical needs, leading to planned registrational studies starting summer 2026, including the TEMPO-1 trial for OPSCC. The data will be presented at the 2026 ASCO Annual Meeting, highlighting CRB-701's potential as a new treatment option for HPV-driven cancers with limited current therapies.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
